Key Aspects of Clarity-IA Explained by CEO

BATAVIA, New York – November 22, 2022 – First Wave Technologies, Inc. (“First Wave” “FWT” and “Company”), a medical device company developing products for the acute care and long-term care markets, announces it has been recognized by MedTech Outlook as the Company of the Year-Top MedTech Startup. The award highlights First Wave’s Clarity-IA® advanced inhalational medical gas delivery system.

MedTech Outlook, a leading industry publication, works to monitor and inform the healthcare industry about innovative MedTech trends and solutions that can have meaningful impact on healthcare providers and patients. As such, MedTech Outlook aims to bridge the information gap between MedTech technology, providers, healthcare facilities, and medical institutions.

Regarding this acknowledgement, Brian Bell, CEO of First Wave stated, “We are very pleased to see that MedTech Outlook selected First Wave as a recipient of this award. It is an honor to be recognized amongst today’s landscape of emerging and innovative healthcare products.  With Clarity-IA having a strong IP foundation (58 patents/applications) and a 510(k) in progress, the timing of the award is appropriate.  First Wave also acknowledges the contributions of the Company’s Board of Directors and team members along with the expert physicians and other medical professionals who will be overseeing Clarity-IA’s planned clinical trials.  First Wave’s ultimate goal is to offer cost savings to the overall healthcare system and offer the highest level of care to patients needing inhaled anesthesia.

Further information about First Wave, as shared by Mr. Bell in this feature article, can be found on the MedTech Outlook website as well as on the Company’s corporate website.

About First Wave Technologies, Inc.
First Wave Technologies, Inc. is a medical device company developing products for the acute care and long-term care markets. The focus is to disrupt areas of healthcare with innovative products which have not seen meaningful change historically for the improvement of patient care. Current products are centered around improving the ease and accuracy of pharmaceutical delivery. For more information, please visit

Corporate Contact:
Brian Bell
Chief Executive Officer and Director
First Wave Technologies, Inc.
99 MedTech Dr. 
Batavia, New York 14020
Phone: +1 877.784.0269

Investor Contact:
Jennifer K. Zimmons, Ph.D., MBA
Investor Relations
Zimmons International Communications, Inc.
Phone: +1 917.214.3514

This press release contains forward-looking information that involves various risks and uncertainties regarding future events related to our IsoVENT and our partnership with Canon. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements and are not guarantees of future performance of the Company. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. These forward-looking statements reflect management’s current views and are based on certain expectations, estimates and assumptions which may prove to be incorrect. A number of risks and uncertainties could cause our actual results to differ materially from those expressed or implied by the forward-looking statements, including: (1) a downturn in general economic conditions in North America and internationally, (2) the inherent uncertainties and speculative nature associated with the development and commercialization of technology and the practice of medicine, (3) a change in health regulations, (4) any number of events or causes which may delay or cease commercialization and development of the IsoVENT device, (5) the risk that the Company does not execute its business plan or that the companies engaged to develop and obtain regulatory approval for the IsoVENT device do not execute their plans, (6) inability to retain key employees, (7) inability to finance operations and growth, and (8) other factors beyond the Company’s control. These forward-looking statements are made as of the date of this news release and, except as required by law, the Company assumes no obligation to update these forward-looking statements, or to update the reasons why actual results differed from those projected in the forward-looking statements.